FGFR2
- Known as:
- FGFR2
- Catalog number:
- Y214020
- Product Quantity:
- 200ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- FGFR2
Related genes to: FGFR2
- Gene:
- FGFR2 NIH gene
- Name:
- fibroblast growth factor receptor 2
- Previous symbol:
- KGFR, BEK, CFD1, JWS
- Synonyms:
- CEK3, TK14, TK25, ECT1, K-SAM, CD332
- Chromosome:
- 10q26.13
- Locus Type:
- gene with protein product
- Date approved:
- 1991-05-09
- Date modifiied:
- 2019-04-23
Related products to: FGFR2
Related articles to: FGFR2
- Soft tissue sarcomas are malignant neoplasms originating from mesenchymal cells. In cats, there are two groups: inoculation site-associated sarcomas (ISSs) and non-inoculation site-associated sarcomas (NISSs). The aim of this study was to investigate the immunoexpression of metalloproteinases (MMPs) 2 and 9, tissue inhibitors (TIMPs) 1 and 2, and the main molecules related to angiogenesis and vascular count in both sarcoma groups; compare their expression; and evaluate their association with angiogenesis. Both tumor groups expressed all the molecules evaluated. A positive correlation was detected between MMP-2 and angiogenic factors in both ISSs and NISSs. MMP-9 expression correlated positively with MMP-2 in both groups. TIMP-1 correlated with both MMP and with angiogenic factors in ISS. Fibroblast growth factor receptor 2 (FGFR-2) expression was higher in NISS. Studying the pathways that regulate angiogenesis in these neoplasms is crucial for identifying ways to intervene and limit neoplastic progression, thereby developing new therapeutic approaches. - Source: PubMed
Publication date: 2026/08/06
Wright CarolinaScarano Alejo CarlosVerdes José ManuelScenna Silvana GracielaDuchene Adriana GracielaOsacar Juan ManuelDi Pierro Lucas MartínRisso PaulaBadura ErikaBarbeito Claudio GustavoAcuña FranciscoSantelices Iglesias Olga Andrea - - Source: PubMed
Publication date: 2026/08/12
Saj FenGoyal Lipika - - Source: PubMed
Publication date: 2026/08/12
Reddy NihaalVasiljevic KatarinaShatsky Rebecca - Colorectal cancer (CRC) is a common malignancy worldwide, and its progression is associated with dysregulated signaling pathways. Fibroblast growth factor receptor 2 (FGFR2) is frequently overexpressed in CRC and correlated with poor prognosis, but whether it mediates hypoxia-inducible factor-1α (HIF-1α) to promote tumor progression remains unclear. - Source: PubMed
Publication date: 2026/08/06
Hu YiyangYao LiuxuLi YuhongWang HongFaHuang HuangFang JunbiaoLuo Foquan - Alzheimer's Disease (AD) is a neurodegenerative disorder that characterizes depletion of memory, cognition, and a change in behavioural patterns. There is no standard treatment that completely cures this prevalent disease. This review delves into the existing pathologies of AD, which include the Aβ plaques accumulation, neurofibrillary tangles and Lewy bodies formation, and the influence of the P2X7 receptor on cellular mechanisms of neuronal cells like microglial cells, astrocytes and oligodendrocytes and also its influence on pathways such as JAK2/STAT3, NGF signalling, (Transactive response DNA binding protein) TDP-43 Proteinopathy, Wnt/β-Catenin signalling, and FGF7/FGFR2/PI3K/Akt causing AD. It discusses the unifying role of the P2X7 receptor mediating these pathways that link to the occurrence and progression of AD. The role of the Purinergic receptor (P2X7 receptor), a ligand-gated ion channel activated by extracellular ATP, was examined across existing cellular mechanisms and possible pathways involved in AD, as well as the co-pathologies encompassed and their hypothetical relationship with the P2X7 receptor. Additionally, the current P2X7 receptor antagonists treating neurotoxicity are discussed along with existing pre-clinical and clinical data. This may further advance drug development by targeting the P2X7 receptor to mitigate AD across multiple mechanisms. - Source: PubMed
Publication date: 2026/07/30
Jeeru Tejaswini ReddyPalathoti NagarjunaSwaminathan Gomathi